Literature DB >> 34878801

Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.

Sharon H Giordano1, Rachel A Freedman2, Mark R Somerfield3.   

Abstract

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34878801     DOI: 10.1200/JCO.21.02677

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  6 in total

1.  Additive pharmacological interaction between sirtuin inhibitor cambinol and paclitaxel in MCF7 luminal and MDA-MB-231 triple-negative breast cancer cells.

Authors:  Anna Wawruszak; Estera Okon; Ilona Telejko; Arkadiusz Czerwonka; Jarogniew Luszczki
Journal:  Pharmacol Rep       Date:  2022-07-28       Impact factor: 3.919

2.  Correlation of the Ki67 Working Group prognostic risk categories with the Oncotype DX Recurrence Score in early breast cancer.

Authors:  Rima Patel; Malin Hovstadius; Melanie W Kier; Erin L Moshier; Brittney S Zimmerman; Krystal Cascetta; Shabnam Jaffer; Joseph A Sparano; Amy Tiersten
Journal:  Cancer       Date:  2022-08-10       Impact factor: 6.921

3.  A Nomogram for Predicting Liver Metastasis of Lymph-Node Positive Luminal B HER2 Negative Subtype Breast Cancer by Analyzing the Clinicopathological Characteristics of Patients with Breast Cancer.

Authors:  Yuhan Yue; Junqing Liang; Yuruo Wu; Weibing Tong; Dan Li; Xuchen Cao; Xin Wang
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 4.  Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality.

Authors:  Amanda J Kerr; David Dodwell; Paul McGale; Francesca Holt; Fran Duane; Gurdeep Mannu; Sarah C Darby; Carolyn W Taylor
Journal:  Cancer Treat Rev       Date:  2022-03-04       Impact factor: 13.608

Review 5.  Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer-A Literature Review.

Authors:  Danilo Giffoni de Mello Morais Mata; Carlos Amir Carmona; Andrea Eisen; Maureen Trudeau
Journal:  Curr Oncol       Date:  2022-07-13       Impact factor: 3.109

6.  COL11A1 serves as a biomarker for poor prognosis and correlates with immune infiltration in breast cancer.

Authors:  Qi Luo; Jinsui Li; Xiaohan Su; Qiao Tan; Fangfang Zhou; Shaoli Xie
Journal:  Front Genet       Date:  2022-09-09       Impact factor: 4.772

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.